China granted Grand Pharmaceutical's (HKG:0512) nuclear medicine research and development and production facility in Wenjiang, Chengdu, China, obtained a class A radiation safety license.
The facility will start operating in June this year after passing the environmental assessment conducted in April 2023, according to a Sunday filing with the Hong Kong bourse.
Grand Pharma invested more than 3 billion yuan for the facility, which will focus on isotope process development and preparation, nuclear medicine coupling technology, and automated labeling technology, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.